Octimet Oncology
Pre-clinicalOCTIMET oncology’s overall strategy is to develop cMET inhibitor and other highly selective anti-tumour molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development approaches.
Founded
2014
Focus
Small Molecules
About
OCTIMET oncology’s overall strategy is to develop cMET inhibitor and other highly selective anti-tumour molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development approaches.
Funding History
2Total raised: $49M
Series B$30MForbionDec 15, 2020
Series A$19MForbionJun 15, 2018
Company Info
TypePrivate
Founded2014
LocationLeuven, Belgium
StagePre-clinical
Contact
SIMILAR COMPANIES
Miracor Medical
Pre-clinical · Zaventem
AML Clinical Services
Pre-clinical · Leuven
Anacura
Pre-clinical · Ghent
Aseptic Technologies
Pre-clinical · Gembloux
Aspect Analytics
Pre-clinical · Leuven
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile